A Trial on the Remission Rates of Type I Autoimmune Pancreatits With High-risk of Recurrence

Inclusion Criteria: 1. Signed informed consent form with date; 2. Promise to comply with research procedures and cooperate with the implementation of the entire process research; 3. Age 18 and above, regardless of gender; 4. Confirmed as type I AIP and high-risk for recurrence, including the following characteristics: IgG4\>4 times the upper limit of normal value before treatment; The serum IgG4 level remained high after GC treatment; Pancreatic diffuse enlargement; IgG4-SC with proximal bile duct involvement; Involvement of extrapancreatic organs; 5. Indications for treatment, (1) symptomatic individuals may experience pancreatic involvement (such as obstructive jaundice, abdominal pain, lower back pain, etc.) and extrapancreatic organ involvement (such as jaundice caused by bile duct stenosis, etc.); (2) Asymptomatic individuals, who may develop subclinical AIP (persistent pancreatic mass, liver dysfunction with proximal IgG4 associated sclerosing cholangitis) with severe and irreversible damage to important organs; 6. Able to persist and cooperate with research interventions, such as oral medication; 7. If it is a woman in the reproductive period, contraception should be used for at least one month before screening, and a commitment should be made to use contraception throughout the entire study period and continue until the specified time after the end of the study Exclusion Criteria: 1. Pregnant/lactating women; Inability or refusal to sign informed consent form; 2. History of mental illness; 3. Allergy to research interventions; 4. With malignant tumors; 5. Active hepatitis/tuberculosis and other infectious diseases; 6. With underlying diseases that are difficult to control, such as severe heart failure, respiratory failure, etc; 7. Within 3 months, use of glucocorticoids or immunosuppressants due to other illnesses